PCI Biotech and RXi Pharmaceuticals Extend Research Collaboration to the Field of Immuno-oncology
Oslo (Norway), 22 May 2017 - PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, and RXi Pharmaceuticals (NASDAQ: RXII) a biotechnology company focused on developing novel RNAi therapeutics for significant un-met needs, today announced that they are extending their preclinical research collaboration initiated April 7, 2015.
This extension is supported by a new preclinical research collaboration agreement that reflect RXi's recently completed acquisition of MirImmune and PCI Biotech's focus in oncology. In brief, the preclinical research collaboration will evaluate technology compatibility and synergy based on in vivo studies. The companies will evaluate results achieved from this research collaboration and then explore the potential for a further partnership.
Please see attached press release for further details.
About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms:
fima
Chem
(enhancement of chemotherapeutics for localised treatment of cancer),
fima
Vacc
(T-cell induction technology for therapeutic vaccination), and
fima
NAc
(nucleic acid therapeutics delivery).
Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company's lead
fima
Chem
programme consists of a clinical Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products.
fima
Vacc
applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies.
fima
NAc
utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo, Norway.
www.pcibiotech.com
Per Walday, CEO,
pw@pcibiotech.com
, Mobile: +47 917 93 429.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PCI Biotech Holding via GlobeNewswire
Upcoming Life Sciences Events
- April 2024
- London: BioTrinity 2024
- Singapore: Asia Bio Partnering Forum
- London: LSX World Congress
Latest company news
There are currently no news available for this portal